HEAD-TO-HEAD

CJC-1295 VS SERMORELIN

Both are GHRH-receptor agonists used in GH-axis research. Sermorelin is the native unmodified GHRH(1-29) sequence with rapid DPP-IV cleavage and ~10-20 min half-life. CJC-1295 is the same parent sequence with four stabilizing substitutions resisting DPP-IV (Mod GRF 1-29, No DAC variant ~30 min half-life) or an additional albumin-binding DAC linker (~1 week half-life). CJC-1295 is the modern research-protocol choice; sermorelin retains historical and pediatric-GHD relevance as the former FDA-approved Geref formulation.

A · No. 032HP 135

CJC-1295

Stabilized GHRH Analog · With/No DAC

B · No. 030HP 110

SERMORELIN

GHRH(1-29) Native Fragment

SIDE BY SIDE

FIELD

A · CJC-1295

B · SERMORELIN

Parent sequence

GHRH(1-29) with 4 stabilizing substitutions

Native GHRH(1-29)

DPP-IV resistance

Yes (Ala2->D-Ala, Arg15->Gln, Leu27->Ala, Asp28->Ser)

No · native sequence is rapidly cleaved

Half-life

~30 min (No DAC) · ~1 week (with DAC)

~10-20 minutes

Albumin tethering

Yes in with-DAC variant (MPA linker)

Best paired GHS partner

Ipamorelin (standard CJC-1295 No DAC stack)

Ipamorelin (less commonly used than CJC-1295)

FDA history

Never FDA-approved · ConjuChem with-DAC program halted (2 trial deaths)

Previously approved as Geref (1997) for pediatric GHD · withdrawn for commercial reasons

WADA status

Prohibited at all times (S2 GHRH-analog)

WHICH IS BETTER · BY GOAL

▶ Practical research dosing frequencyA · CJC-1295

CJC-1295 No DAC's DPP-IV resistance extends effective receptor engagement vs sermorelin's rapid clearance. With-DAC variant extends further to weekly dosing.

▶ Pediatric GH deficiency (historical)B · SERMORELIN

Sermorelin had FDA approval as Geref. CJC-1295 has no approved indication anywhere.

▶ Modern research-protocol useA · CJC-1295

CJC-1295 No DAC (Mod GRF 1-29) is the standard GHRH partner in modern research stacks with ipamorelin. Sermorelin is rarely used outside historical reference.

▶ Long-term safety recordB · SERMORELIN

Sermorelin's history as approved Geref provides longer documented safety data. CJC-1295 with-DAC has two deaths in a lipodystrophy trial that halted the ConjuChem program.

▶ Natural pulse mimicryB · SERMORELIN

Sermorelin's short native half-life produces a pulse closer to the natural pulsatile GH rhythm. CJC-1295 No DAC is similar; with-DAC variant produces sustained low-level GH bleed rather than pulses.

STACKING NOTE

CJC-1295 and sermorelin are not stacked together · they are functional substitutes (both GHRH-receptor agonists). Choose one as the GHRH arm and pair with a ghrelin-receptor agonist (ipamorelin standard, GHRP-2 or hexarelin alternatives). Sermorelin+ipamorelin is the historical pairing; CJC-1295 No DAC + ipamorelin is the modern standard.

SOURCED FROM PEPPU LABS

Both compounds are available as research-grade material at Peppu Studio · ≥99% purity · per-batch CoA. For laboratory research use only.

SOURCE CJC-1295 ▶SOURCE SERMORELIN ▶